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Abstract
Introduction In humans, an early full-term pregnancy reduces
lifetime breast cancer risk by up to 50% whereas a later
pregnancy (>35 years old) can increase lifetime risk. Several
mechanisms have been suggested, including changes in levels
of circulating hormones, changes in the way the breast
responds to these hormones, changes in gene expression
programmes which may alter susceptibility to transformation
and changes to mammary stem cell numbers or behaviour.
Previous studies have shown that the mammary tissue isolated
from both virgin and parous mice has the ability to repopulate a
cleared mammary fat pad in transplant experiments. Limited
dilution transplant assays have demonstrated that early
pregnancy (at 5 weeks of age) reduces stem/progenitor cell
numbers in the mouse mammary epithelium by twofold.
However, the effects on stem/progenitor cell numbers in the
mammary epithelium of a pregnancy in older animals have not
yet been tested.
Methods Mice were put through a full-term pregnancy at 9
weeks of age, when the mammary epithelium is mature. The total
mammary epithelium was purified from parous 7-week post-
lactation and age-matched virgin mice and analysed by flow
cytometry and limiting dilution cleared fat pad transplants.
Results There were no significant differences in the proportions
of different mammary epithelial cell populations or numbers of
CD24+/Low Sca-1- CD49fHigh cells (stem cell enriched basal
mammary epithelial compartment). There was no significant
difference in stem/progenitor cell frequency based on limiting
dilution transplants between the parous and age-matched virgin
epithelium.
Conclusions Although differences between parous and virgin
mammary epithelium at later time points post lactation or
following multiple pregnancies cannot be ruled out, there are no
differences in stem/progenitor cell numbers between mammary
epithelium isolated from parous animals which were mated at 9
weeks old and virgin animals. However, a recent report has
suggested that animals that were mated at 5 weeks old have a
twofold reduction in stem/progenitor cell numbers. This is of
interest given the association between early, but not late,
pregnancy and breast cancer risk reduction in humans.
However, a mechanistic connection between stem cell numbers
and breast cancer risk remains to be established.
Introduction
It is well established that pregnancy has a profound effect on
breast cancer risk [1] (reviewed in [2]). Breast cancer risk is
significantly increased immediately after parturition and this
elevated risk can last for a period of 5 to 10 years in humans
[3,4]. Once this elevated risk period is past, however, breast
cancer risk drops in women who have had an early first full-
term pregnancy to below the levels of nulliparous women of a
similar age. The eventual risk decrease is more profound the
earlier the age at which the first full-term pregnancy occurs
[1,3,5]; a woman who has a first full-term pregnancy under the
age of 20 can reduce her lifetime risk of breast cancer by 50%,
even allowing for the increased risk period immediately after
parturition [1]. In contrast, first full-term births over the age ofPage 1 of 15
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AMV: age-matched virgin; DAPI: 4,6-diamidino-2-phenylindole dihydrochloride; DMEM: Dulbecco's modified Eagle's medium; ER: oestrogen recep-
tor; FCS: foetal calf serum; FITC: fluorescein isothiocyanate; GFP: green fluorescent protein; H & E: haemotoxylin and eosin; PBS: phosphate-buff-
ered saline; PE: phycoerythrin; PR: progesterone receptor.
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Interestingly, this lifetime protective effect is limited to oestro-
gen receptor-positive/progesterone receptor-positive
(ER+PR+) breast cancers and is not seen for other breast
tumour types [2]. Both parity and parity-like oestrogen treat-
ment can also protect rodents against the development of hor-
mone-dependent carcinogen-induced mammary tumours [6-
8].
The mechanism or mechanisms behind these effects remain
unclear, although several have been proposed and we have
recently discussed these in detail [2]. In brief, four potential
mechanisms have received most attention. First, changes in
levels of circulating hormones such as oestradiol, prolactin
and growth hormone may mediate the effects of pregnancy on
breast cancer risk. Second, changes in the way the mammary
epithelium senses hormones after pregnancy may alter its
response to them. Third, changes in gene expression pro-
grammes in mammary cells after pregnancy may alter the sus-
ceptibility of the cells to transformation. Finally, the proliferative
stimulus of pregnancy on stem cells and alveolar progenitors
with pre-existing genetic lesions might account for the
increase in breast cancer risk during and immediately after
pregnancy. Conversely, a proportion of mammary stem/pro-
genitor cells that do not carry mutations (presumably the
majority) could be forced to permanently differentiate by the
stimulus of pregnancy, resulting in a reduction in the numbers
of a cell population at high risk of transformation [9] and there-
fore a reduction in the lifetime risk of breast cancer.
In the present study, we address the possibility that the alter-
ations in the ER+PR+ breast cancer risk profile caused by par-
ity are a result of changes in mammary epithelial stem/
progenitor activity following pregnancy. Epidemiological stud-
ies have shown that women who are prenatally exposed to
restricted oestrogens (associated with preeclampsia) have a
decreased risk of developing breast cancer, whilst those who
are prenatally exposed to increased levels (diethylstilbestrol or
oestrogen treatment) or who experience menarche (associ-
ated with high oestrogen levels) at a young age are at an
increased risk (reviewed in [2]). This sensitivity to oestrogen
occurs at stages when mammary stem cells are thought to be
the most active in the developing breast (during prenatal
development and during puberty) [7] and are undergoing both
symmetric and asymmetric divisions to produce the stem cell
pool and differentiated daughters required for the mature func-
tional mammary gland. Furthermore, although the mammary
epithelial stem cells of the adult gland are ERα-negative
[10,11], they may still be responsive to oestrogen exposure. In
ER- spermatogonial and endometrial stem cells, oestrogen has
been shown to affect stem cell proliferation [12,13] – and we
have recently demonstrated that ER+ differentiated mammary
epithelial cells do not have an oestrogen-responsive gene sig-
nature as defined by other studies. Rather, many of the genes
whose expression has previously been reported to be stimu-
lated by oestrogen in breast cancer cell lines [14-16] are actu-
ally most strongly expressed in basal/myoepithelial cells [17].
The effects of oestrogen on adult stem cells may therefore be
partly ER independent. Also clear, however, is that oestrogen
affects ER- mammary stem cells via paracrine interactions with
ER+ differentiated cells [17-21].
Until recently, only limited direct experimental evidence existed
on whether mammary stem behaviour is altered by pregnancy.
A previous study that assessed transplantation rates in virgin
mice and parous regressed animals found no differences [22].
Whether the virgin and parous animals were age matched, or
for how many weeks post weaning the parous animals had
been allowed to involute, however, was unclear. Furthermore,
the study used microdissected pieces of tissue, not limited
dilution assays of known cell numbers, so the numbers of cells
transplanted cannot be compared. While the current manu-
script was being prepared, however, Siwko and colleagues
reported a study in which pregnancy in young mice (mated at
5 weeks of age) resulted in a twofold reduction in the numbers
of stem/progenitor cells [23].
The mammary epithelium is composed of two main cell types,
the basal cells and the luminal cells. The basal cell layer is
mainly composed of myoepithelial cells but also contains the
mammary epithelial stem cell compartment in both the mouse
and human breast [11,24-28]. The mammary epithelium is also
thought to contain a number of progenitor cell types down-
stream of the stem cells, with good evidence existing in partic-
ular for a progenitor cell for the milk-producing alveoli of
pregnancy in the luminal epithelial cell layer [28-32]. Evidence
also exists from bromodeoxyuridine labelling strategies for a
distinct lineage of progenitors for ER-expressing cells [33,34].
We have previously used a cell separation strategy based on
expression of CD24 and Sca-1 to isolate and characterise pri-
mary mouse mammary cells from 10-week-old to 12-week-old
virgin mice. We showed that the basal cell population has a
CD24+/Low Sca-1- staining pattern, the luminal ER- cells are
CD24+/High Sca-1- and the luminal ER+ cells are CD24+/High
Sca-1+. We also showed that the ER+ cells of the mammary
gland have little or no transplant activity in cleared fat pad
transplant assays but that, consistent with other reports, stem
cell activity is concentrated in the basal cell layer and can be
enriched by isolation of CD24+/Low cells that express high lev-
els of α6 integrin (CD49f) [11,26,27]. No strategy yet exists for
unequivocal isolation of pure basal stem cells, however, and
some progenitor activity can be identified in the other popula-
tions [11]. We therefore employed our CD24 and Sca-1 sort-
ing strategy to purify the total epithelial compartment from the
mammary fat pads of parous 7-week post-lactation and age-
matched virgin (AMV) mice, and analysed these total epithelial
preparations by limited dilution transplantation for changes in
stem/progenitor cell activity. We used mice that were mated
at 9 weeks of age, when the mammary epithelium is essentiallyPage 2 of 15
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their animals during mid-puberty [23]. In contrast to Siwko and
colleagues, we find that a pregnancy in mice with developmen-
tally mature mammary tissue does not affect stem/progenitor
cell numbers. Taken together, our results and those of Siwko
and colleagues support a model in which early, but not late,
pregnancy depletes mammary epithelial stem cells.
Materials and methods
Animals
All animal work was carried out under UK Home Office project
and personal licences following local ethical approval and in
accordance with local and national guidelines. Parous mice
were obtained by mating 9-week-old FVB females and allow-
ing normal parturition, lactation and weaning of pups (at 21
days post partum). The parous animals were then left to
undergo mammary gland involution and remodelling for a fur-
ther 7 weeks. Tissue was harvested for transplant at 22 weeks
of age (Figure 1a). AMV FVB females were used as controls.
Isolation, staining and flow cytometric analysis of 
primary mouse mammary cells
The procedure for isolation of primary mouse mammary cells,
their staining and separation by flow cytometry has been pre-
viously described in detail [26]. In brief, fourth (abdominal)
mouse mammary fat pads from FVB mice were processed by
mechanical and enzymatic dissociation to liberate single cells.
Cells were stained with anti-CD24-FITC (clone M1/69, 0.5
μg/ml; BD Biosciences, Oxford, UK), anti-CD45-PE-Cy7
(clone 30-F11, 0.25 μg/ml; BD Biosciences), anti-Sca-1-PE
(clone D7, 0.5 μg/ml; BD Biosciences) and anti-CD49f-PE-
Cy5 (clone GoH3, 5 μl/106 cells; BD Biosciences). To stand-
ardise gating on CD49fHigh mammary epithelial cells, we used
5% interval linear density contour plots (see Additional data
file 1) and considered the outer edge of the main body of the
CD24+/Low cells, as defined by the contour plots, to be the limit
above which cells can be considered CD49fHigh.
For analysis of green fluorescent protein (GFP)-expressing
cells isolated from transplanted fat pads, anti-CD24-FITC was
replaced with anti-CD24-PE-Cy5 (clone M1/69, 0.6 μg/ml;
eBioscience, Insight Biotechnology Limited, London, UK) and
the anti-CD49f-PE-Cy5 was not used.
Cells were sorted on a FACSAria (BD Biosciences) equipped
with violet (404 nm), blue (488 nm), green (532 nm), yellow
(561 nm) and red (635 nm) lasers. Both cell sample and col-
lection tubes were maintained at 4°C. Dead cells, CD45+ leu-
kocytes and nonsingle cells were excluded as described [26].
There was no difference in viability of parous and AMV cells
detectable during sorting.
Lentivirus production
Viral supernatants were generated by co-transfection of the
expression vector pWPI and two packaging vectors (psPAX2
and pMD2.G) (Tronolab [35]) into HEK293T cells. Cells were
re-fed with fresh medium (DMEM; Invitrogen, Paisley, UK) plus
10% FCS (PAA Laboratories, Yeovil, UK) after 24 hours.
Supernatants were harvested 48 and 72 hours after transfec-
tion and were checked for absence of replication-competent
virus. Supernatants were stored at -80°C until use.
Mammary epithelial cell transduction and 
transplantation
Freshly isolated primary mouse mammary epithelial cells were
resuspended at 1 × 106 cells/ml in viral supernatant and
plated at 1 ml/well in ultra-low attachment 24-well plates
(Corning, Fisher Scientific, Loughborough, UK) [36]. After 16
hours, the cells (now in clumps) were washed and replated in
1:1 DMEM:Ham's F12 medium (Invitrogen) with 10% FCS, 10
μg/ml insulin (Sigma, Poole, UK), 100 ng/ml epidermal growth
factor (Sigma) and 10 ng/ml cholera toxin (Sigma) (growth
medium) [37] and were transferred to ultra-low attachment six-
well plates (Corning), usually combining the contents of four
wells of the 24-well plates into one well of a six-well plate. After
a further 24 hours, all of the cells were pooled, washed in PBS
and resuspended in a volume of serum-free Leibowitz L15
medium (Invitrogen) such that entire volume of cells would be
evenly distributed among all the cleared fat pads to be injected
(for instance, given that the maximum injection volume per fat
pad was 10 μl, if 10 fat pads were to be injected then the cells
were resuspended in 100 μl). This ensured that the maximum
number of cells per fat pad would be transplanted in order to
guarantee successful outgrowths for subsequent analysis.
The cells were injected into cleared fat pads as described [26]
and were analysed after 8 weeks by mechanical/enzymatic
digestion and flow cytometry as described above.
To estimate viral transduction efficiency, an aliquot of trans-
duced cells was taken from those being used for the trans-
plants and was maintained in culture for 1 week to allow time
for expression of the GFP (which is not expressed immediately
after transduction, making it difficult to estimate the transduc-
tion efficiency directly prior to transplantation). The percent-
age of GFP-positive cells was then measured either by flow
cytometry or direct visualisation of cells cultured on coverslips.
Using these methods, transduction efficiencies of between
40% and 90%, depending on the experiment, were deter-
mined.
Limited dilution cleared fat pad transplantation of 
mammary cells to determine stem/progenitor cell 
frequencies
Analysis of stem/progenitor cell capacity of mammary cell pop-
ulations by limited dilution transplantation into cleared mam-
mary fat pads has been previously described in detail [11,26].
Primary mammary epithelial cells were freshly isolated from
mouse mammary glands and immediately stained and flow
sorted (with no intervening culture period). Using the flow
cytometry gates defined by analysis of GFP-transduced mam-Page 3 of 15
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Figure 1
Seven-week post-lactation mouse mammary epithelium is fully regenerated and similar to age-matched virgin tissue. (a) Outline of experimental 
design. Mice were mated at 9 weeks of age, went through a normal pregnancy and nursed pups for 3 weeks. Involution occurred over an approxi-
mately 3-week period after pups were removed. After a further 4 weeks, when the animals were in total 22 weeks old, tissue was harvested. (b), (d) 
Carmine-stained whole mount of age-matched virgin (AMV) fourth mammary fat pad. (c), (e) Carmine-stained whole mount of parous fourth mam-
mary fat pad. (b), (c) Bar = 3 mm. (d), (e) Bar = 750 μm. (f) H & E-stained section of AMV fourth mammary fat pad. Bar = 20 μm. (g) H & E-stained 
section of parous (7-week post-lactation) fourth mammary fat pad. Bar = 20 μm. (h) H & E-stained section of parous (3-week post-lactation) fourth 
mammary fat pad showing collapsed ducts (arrowheads). Bar = 20 μm.
Available online http://breast-cancer-research.com/content/11/2/R20mary epithelial cells, purified total epithelial cells (CD24+/Low
Sca-1- cells plus the total CD24High population) were isolated.
The cells were immediately counted and resuspended in
serum-free L15 medium at varying concentrations (for
instance, 20,000, 10,000 or 5,000 cells in 10 μl, the injection
volume). The cells were then transplanted into cleared fat
pads. They did not undergo any in vitro culture, unlike the cells
used for viral transduction. After 8 weeks, the transplanted fat
pads were whole-mounted and carmine-stained to determine
the number and extent of any successful outgrowths. The pro-
portion of stem/progenitor cells was determined using the L-
Calc limiting dilution statistical analysis program [27].
Keratin 14/keratin 18/ER immunofluorescence staining 
of paraffin sections
Antigen sites were retrieved by microwaving in 0.01 M citrate
buffer, pH 6. Nonspecific immunoreactivity was blocked with
MOM mouse immunoglobulin blocking reagent (stock MOM
immunoglobulin blocking reagent in 250 μl Tris-buffered
saline; Vector Laboratories, Peterborough, UK) and 30 min-
utes in DAKO protein block (DAKO, Ely, UK). Sections were
incubated with antibodies against keratin 14 (mouse IgG3
clone LLOO2, 1:500 dilution; Abcam, Cambridge, UK) and
keratin 18 (mouse IgG1 clone Ks18.04, 1:2 dilution; Progen,
Heidelberg, Germany) or keratin 14 and ER (mouse IgG1
clone 1D5, 1:40 dilution; DAKO) overnight at 4°C. After wash-
ing in 0.05% Tween in Tris-buffered saline, sections were
stained with goat anti-mouse IgG3-Alexa488 (1:500 dilution;
Invitrogen) and IgG1-Alexa555 (conjugated in-house accord-
ing to the manufacturer's instructions using Sigma anti-mouse
IgG3 antibody and the AlexaFluor-555 protein labelling kit; Inv-
itrogen). Sections were washed, counterstained with DAPI
and mounted in Vectashield (Vector Laboratories).
All sections were examined on a TCS SP2 confocal micro-
scope with an Acousto-Optical Beam Splitter and lasers excit-
ing at 405 nm, 488 nm and 555 nm (Leica Microsystems,
Milton Keynes, UK). Multicolour images were collected
sequentially in three channels and captured using the Leica
system and Leica TCS image acquisition software. Co-locali-
sation overlays were generated using TCS software. Single
antibody-stained control sections either lacking the first anti-
body or in which the primary antibody was combined with an
inappropriate second antibody were used to confirm lack of
nonspecific staining and cross-reactivity between secondary
and primary antibodies.
Results and discussion
Seven-week post-lactation mice have fully regenerated 
the mammary epithelium
The strategy for preparing 7-week post-lactation (hereafter
termed parous) mice is shown diagrammatically in Figure 1a.
To confirm that these animals had completely regenerated
their mammary epithelium and were structurally similar to AMV
animals, whole-mount analysis and histological examination of
mammary fat pads from mice taken at the same point in the
oestrus cycle (at oestrus) were compared.
On the basis of these analyses, the mammary epithelium from
parous animals had completely regenerated following post-
lactational involution and at a gross morphological level was
very similar to that of AMV animals (Figure 1b to 1e). H & E
sections of parous and AMV glands showed that both had
well-defined ducts and alveolar structures although there were
differences in nuclear morphology between them (Figure 1f,
g). In contrast to the well-defined ducts of the AMV and parous
animals, sections through fat pads isolated from animals at 3
weeks post lactation showed that the tissue contained many
collapsed ducts that had not yet returned to the normal resting
morphology (Figure 1h).
Mammary cells from parous and AMV animals have 
similar flow cytometry profiles
We have previously used CD24 and Sca-1 reactivity to purify
epithelial cells from virgin mouse mammary tissue [11]. Basal
cells were CD24+/Low Sca-1- and consisted mainly of myoepi-
thelial cells but also included the stem cells, which could be
further enriched by sorting for α6 integrin (CD49f) expression,
supporting a previous report [27]. The luminal cells were
CD24+/High and could be divided in to CD24+/High Sca-1- ER-
and CD24+/High Sca-1+ ER+. To determine whether parity
might change the CD24 Sca-1 CD49f flow cytometry profile
of mammary cells and, in particular, whether changes might
occur to the CD24+/Low Sca-1- CD49fHigh stem-cell-enriched
population, mammary cell preparations from parous and AMV
animals were stained for expression of these markers and
were analysed by flow cytometry.
The analysis results (Figure 2) showed that there were no sig-
nificant differences between the cell preparations. In particu-
lar, the percentage of CD24+/Low Sca-1- CD49fHigh cells as a
percentage of the total epithelium in the parous animals was
1.50 ± 0.85% (mean ± standard deviation; n = 3 independent
preparations), and in the AMV animals the percentage was
1.37 ± 0.49% (n = 3 independent preparations). There were
also no significant differences between the proportions of
CD24+/Low Sca-1- basal cells, CD24+/High Sca-1- luminal ER-
cells and CD24+/High Sca-1+ luminal ER+ cells in the parous
animals compared with AMV animals (Figure 2c). Consistent
with these data, Siwko and colleagues noted no differences
between the proportion of CD24+ CD29High cells (essentially
equivalent to CD24+/Low CD49fHigh [38]) in virgin mice com-
pared with parous mice [23].
As there were differences between the nuclei in sections of
parous mice compared with AMV animals, the flow cytometry
profiles were analysed for differences in forward or side scat-
ter. Mean scatter values of epithelial cells were normalised to
the mean scatter of the lymphocytes within each sort. The data
(from three independent parous and three independent AMVPage 5 of 15
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Figure 2
CD24 and Sca-1 flow cytometry isolates similar populations in age-matched virgin and parous tissues. (a) Age-matched virgin (AMV) cells and (b) 
parous cells were stained with antibodies against CD24, Sca-1 and CD49f. The CD24 and Sca-1 plots (left panels) identified CD24+/Low Sca-1-, 
CD24+/High Sca-1- and CD24+/High Sca-1+ cells in both AMV and parous cell preparations. Analysis of these populations for CD49f expression (right 
panels) enabled identification of the CD24+/Low Sca-1- CD49fHigh population previously shown to be enriched for mammary stem cells [11,26,27]. 
See also Additional data file 1. (c) Relative abundance of CD24+/Low Sca-1-, CD24+/High Sca-1- and CD24+/High Sca-1+ cells as a percentage of the 
total epithelium in AMV and parous tissue.
Available online http://breast-cancer-research.com/content/11/2/R20sorts; see Additional data files 2 and 3) showed that both the
CD24+/High luminal populations had similar forward scatter val-
ues, whereas the CD24+/Low Sca-1- basal cells had signifi-
cantly smaller forward scatter values than both luminal
populations in the AMV tissue (P < 0.05, t-test on log10-trans-
formed data), suggesting they are smaller than the luminal
cells. Changes in forward scatter with parity were negligible,
with only the forward scatter of the basal cell population show-
ing a significant (P < 0.05, t-test on log10-transformed data)
increase in parous tissue, suggesting a slight increase in mean
size. There were no significant differences in side scatter
between the different populations in either the virgin or the
parous animals and no significant side scatter differences in
parous cells compared with AMV cells.
It has been reported that the p53 function and apoptotic activ-
ity are increased in the parous mammary epithelium [39]. To
determine whether there were viability differences between
AMV and parous tissue, therefore, cell samples that had been
sorted (excluding DAPI+ dead cells) and then immediately
resorted to check for purity were analysed for post-sort viabil-
ity. There were no significant viability differences between the
tissues, with the AMV cells having a post-sort viability of 78.56
± 1.70% (n = 5 independent sorts) and the parous cells a
post-sort viability of 81.63 ± 3.63% (n = 4 independent sorts).
Total mammary epithelium can be reliably purified from 
mouse mammary tissue
To directly address the issue of whether parity changed the
proportion of cells in the mammary epithelium with stem/pro-
genitor cell capacity, a series of limiting dilution transplant
experiments was carried out comparing the ability of cells iso-
lated from parous animals and AMV animals to repopulate a
cleared mouse mammary fat pad. First, we determined that we
could purify the entire mammary epithelial cell population from
mammary fat pads using CD24 and Sca-1 staining. Such a
sorting strategy would ensure that the number of stem/pro-
genitor cells as proportion of the total epithelium only would be
tested by limiting dilution transplants, and the results would
not be biased by parity-dependent changes in numbers of
nonepithelial cells within the gland. Furthermore, as unequivo-
cally pure basal stem cells cannot yet be isolated, and as pro-
genitors with some transplant activity can be identified in other
populations [11], any approach comparing the transplantation
ability of a single epithelial subpopulation (for example,
CD24+/Low Sca-1- CD49fHigh cells) from two different develop-
mental stages may be biased by changes in the purity of stem
cells within the population or changes in the numbers of pro-
genitors in other populations. Testing the total purified epithe-
lium ensures that all cells with potential stem/progenitor
activity will be assayed.
To confirm that we had identified the CD24 and Sca-1 staining
profile that defined the entire epithelium, primary mammary
cells were transduced with a lentivirus expressing GFP and
then transplanted into cleared fat pads. Fat pads were exam-
ined after 8 weeks and were found to contain extensive GFP+
outgrowths (Figure 3a). Successful repopulation of cleared fat
pads is a property of mammary stem/progenitor cells and
results in the generation of a mammary epithelial outgrowth
containing all of the mammary epithelial cell types [11]. The
GFP+ outgrowths must therefore have been derived from
virus-transduced mammary stem/progenitor cells and would
be expected to contain the full range of mammary epithelial
cells labelled with GFP. To test this hypothesis, the GFP+ out-
growths were digested to single cells, stained for CD24 and
Sca-1 expression and analysed by flow cytometry (Figure 3b).
GFP- cells, which would include cells derived from the host fat
pads and transplanted epithelium derived from stem/progeni-
tor cells that had not been transduced with virus, were found
to be either CD24-, CD24+/Low or CD24+/High and either Sca-
1- or Sca-1+. GFP+ cells, however, were found only in the com-
bined CD24+/Low Sca-1-, CD24+/High Sca-1- and CD24+/High
Sca-1+ regions. This confirmed that a flow cytometry sort gate
over these combined areas defined the total mammary epithe-
lium.
Cleared fat pad transplant analysis demonstrates that 
stem/progenitor activity of parous and AMV tissue does 
not differ significantly
Having established that the total mammary epithelium could
be isolated, limiting dilution transplants with total epithelial
cells (Figure 4a) derived from parous and AMV animals were
carried out. The cells were freshly isolated and did not
undergo any in vitro culture period prior to transplantation.
Transplants were examined after 8 weeks (examples of out-
growths are shown in Figure 4b to 4d) and the number of out-
growths and the extent to which they filled the mammary fat
pads were estimated (Figure 4e). The majority of successful
transplants consisted of a spreading ductal network (Figure
4b, c) with secondary branching and alveolar bud-like struc-
tures in the larger outgrowths. A number of outgrowths, how-
ever, appeared to consist of alveolar-type structures only with
no ductal component (Figure 4d).
Small pieces of tissue were dissected out from all outgrowths
and sectioned to confirm their identity (Figure 5a to 5d). Immu-
nostaining of sections through outgrowths for cell-type-spe-
cific markers (keratin 14, keratin 18 and ER) confirmed that all
ductal-type outgrowths (derived from both parous and AMV
animals) included myoepithelial, luminal ER- and luminal ER+
cells (Figure 5e, f). In the alveolar-type transplants, however,
although keratin 18-positive cells could easily be detected
(Figure 5g), the number of keratin 14-positive cells was varia-
ble (compare Figure 5g with Figure 5h) and ER+ cells could
not be observed in the epithelium. They could be observed,
however, in interstitial cells between the alveoli (Figure 5h,
arrows). Again, these findings were similar in both parous and
AMV animals.Page 7 of 15
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Figure 3
Isolation of total epithelial cell populations from mammary epithelium. (a) Whole mount of mammary fat pad transplanted with primary cells trans-
duced with green fluorescent protein (GFP) lentivirus. Arrow, area enlarged in inset. Bar = 2.5 mm. (b) Flow cytometric analysis of transplanted epi-
thelium. The histogram indicates levels of GFP fluorescence in cells isolated from transplanted mammary fat pads. The CD24 Sca-1 staining pattern 
of the total cells (GFP- and GFP+) harvested from the fat pads is shown. The CD24 Sca-1 staining patterns of the GFP- and GFP+ cells are also 
shown separately. GFP+ cells, which must represent the progeny of transduced stem cells, are found only in the CD24+/Low Sca-1-, CD24+/High Sca-
1- and CD24+/High Sca-1+ regions. Data are representative of four independent experiments.
Available online http://breast-cancer-research.com/content/11/2/R20
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Figure 4
Proportion of stem/progenitor cells in mammary epithelium unchanged in parous compared with age-matched virgin tissue. (a) Flow cytometry plot 
of cells isolated from age-matched virgin (AMV) tissue and stained with anti-CD24 and anti-Sca-1 antibodies showing a typical gate used to isolate 
total mammary epithelial cells for transplantation. This gate was based on the data obtained from the lentiviral transduction experiments, which dem-
onstrated that the CD24+/Low Sca-1- plus the total CD24+/High regions defined the entire mammary epithelium. (b) to (d) Carmine stained whole 
mounts showing examples of (b) large ductal outgrowths, (c) small ductal outgrowths and (d) an alveolar structure generated by transplantation. 
Arrow, region enlarged in the inset. Bar = 4 mm. (e) Table of results of limiting dilution transplants indicating the number of outgrowths obtained and 
the number of fat pads transplanted for each cell dilution. The extent to which each outgrowth filled the host fat pad is indicated by the symbols 
below the numbers. Data are from seven independent cell isolation and transplant sessions.
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Figure 5
Outgrowths of transplanted parous and age-matched virgin tissue ir i  ti .  Outgrowths of transplanted parous and age-matched virgin tissue contain basal/
myoepithelial cells, luminal oestrogen receptor-negative (ER-) cells and luminal oestrogen receptor-positive (ER+) cells. (a), (b) H & E-stained section 
of ductal-type transplant outgrowth. (c), (d) H & E-stained section of alveolar-type transplant outgrowth. (a), (c) Bar = 120 μm. (b), (d) Bar = 20 μm. 
(e) to (h) Sections of outgrowth stained by multiple immunofluorescence for cell-type specific markers. All nuclei are counterstained with DAPI 
(blue). Bar = 20 μm. (e) Ductal outgrowth stained for keratin 14 (red) and keratin 18 (green). (f) Ductal outgrowth stained for keratin 14 (red) and ER 
(green). Arrows, examples of ER+ luminal epithelial nuclei. (g) Alveolar outgrowth stained for keratin 14 (red) and keratin 18 (green). (h) Alveolar out-
growth stained for keratin 14 (red) and ER (green). Arrows indicate rare interstitial ER+ cells between alveolar structures.
Available online http://breast-cancer-research.com/content/11/2/R20The rate of successful transplants was used to estimate the
proportion of stem/progenitor cells in each population using
the L-Calc analysis package [27]. The calculations showed
that the AMV animals had a mammary epithelial stem/progen-
itor frequency of 1 in 20,636 cells (95% confidence limits: 1
in 13,157 to 1 in 32,366) and the parous animals had a mam-
mary stem/progenitor frequency of 1 in 18,538 cells (95%
confidence limits: 1 in 11,238 to 1 in 30,580). Stem/progeni-
tor cell frequencies in the AMV cells and the parous cells were
therefore not significantly different following a single preg-
nancy in the mature virgin animal. However, it is possible that
multiple pregnancies and/or increasing the time at which cells
are harvested for assay beyond 7 weeks after weaning may
still alter stem cell numbers following the initial first pregnancy
at 9 weeks of age. Future studies will address these issues.
The alveolar-only outgrowths did not contain cells with detect-
able ER and may have arisen from progenitors with a limited
differentiation potential that did not include the ER+ cell line-
age. Such outgrowths would therefore be incapable of
responding to oestrogen and initiating ductal elongation. A
hierarchy of stem/progenitor cells including ductal–alveolar
progenitors capable of generating the entire mammary epithe-
lium, ductal progenitors that can generate only ducts and alve-
olar progenitors that can generate only alveoli has been
previously suggested [30]. Our results support such a hierar-
chy and suggest that its underlying basis is the cell lineage dif-
ferentiation potential of the outgrowth initiating cells. Whether
such alveolar-only progenitors should be included in calcula-
tions to determine stem/progenitor frequencies, however, is
unclear. We therefore recalculated the stem/progenitor fre-
quencies excluding the transplants that resulted in alveolar
outgrowths from the calculations. Excluding these transplants,
the stem/progenitor cell frequency in the AMV animals was 1
in 33,786 cells (95% confidence limits: 1 in 20,152 to 1 in
56,644) and in the parous animals was 1 in 23,097 cells (95%
confidence limits: 1 in 13,762 to 1 in 38,766), suggesting a
trend towards an increasing number of stem/progenitor cells
specifically with ductal outgrowth potential in the parous tis-
sue. The difference, however, is not statistically significant
[40].
To our knowledge, the presence of alveolar-type outgrowths
with no ductal component in mammary fat pad transplants has
only been reported twice previously, once by us [41] and once
by Smith in the original report describing the phenomenon
[30]. Smith reported that out of 22 transplants from limiting
dilutions (5,000 per fat pad) of mammary epithelial cells, 10
were of the alveolar-only type (Smith terms these lobular). In
the current report, eight out of 22 transplants from the virgin
donors formed alveolar outgrowths, comparable with Smith's
data [30]. In our previous report, four out of five outgrowths
derived from mammary side population cells had the alveolar
phenotype [41]. In both of these previous reports, transplant
host animals were mated prior to whole mounting of fat pads
– and this may have influenced formation of alveolar struc-
tures. In the current report, however, animals were not mated
prior to whole mounting, yet many alveolar type outgrowths
were still observed. In our previous study, the donor animals
were 8-week-old to 10-week-old virgin FVB mice and the use
of side population sorting may have enriched for alveolar pro-
genitors [41,42]. Smith does not make the age of the donor
mice clear [30]; in the current study, the donor mice were 22
weeks old. In our previous transplantation studies in which
cells from 10-week-old virgin FVB mice were transplanted but
the animals were not mated prior to whole mounting, no alve-
olar-only type outgrowths were observed [11,26]. It is there-
fore possible that two factors influence the development of
alveolar-only type structures in cleared fat pad transplantation
– namely increasing age of the donor mice, and induction of
pregnancy in the host mice prior to whole-mount analysis. Fur-
ther transplant experiments will be needed to clarify this issue.
We chose to use flow cytometry based on CD24 and Sca-1
expression profiles to purify the total epithelial cell compart-
ment of parous and AMV mammary epithelium for transplanta-
tion. The benefits of this approach are that it allows
transplantation of a well-defined cell population, it enables
comparison with our previous data [11,26] and it permits
stem/progenitor cell numbers to be measured as a fraction of
the epithelium without possible confounding effects of co-
transplantation of stromal cells that may enhance or suppress
transplantation as a result of their own responses to parity. We
(and others) have previously shown that stem/progenitor cells
in the virgin mouse mammary epithelium are CD24+
[11,24,26,27] and we used GFP-marking and transplantation
to confirm that we could isolate the total mammary epithelium
with our flow sorting strategy. We have only directly demon-
strated this, however, in the virgin animal. We cannot defini-
tively exclude the possibility that this sorting strategy may
exclude some stem/progenitor cells in the parous tissue. Fur-
thermore, the use of purified epithelial populations, rather than
mixed cell isolates, may alter estimates of stem/progenitor cell
potential.
Siwko and colleagues estimate stem/progenitor cell frequen-
cies in the unsorted epithelial cell fractions of AMV and parous
tissue as 1 in 2,608 and 1 in 5,050 cells, respectively. This is
in agreement with a previous estimate of stem/progenitor cell
frequency in unsorted mammary tissue of approximately 1 in
1,400 cells [27] and our own estimates of the frequency of
stem/progenitor cells in unsorted mammary cell isolates of 1 in
2,951 cells (H Kendrick and M Smalley, unpublished data).
These contrast, however, with our estimated stem cell fre-
quency in the purified AMV epithelial cells of 1 in 20,636 cells.
We previously published a limiting dilution transplant series of
basal epithelial cells, luminal ER- cells and luminal ER+ cells
isolated by flow sorting. These series gave estimated stem cell
frequencies in the three populations of 1 in 3,480 for the basal
cells, 1 in 14,317 for the luminal ER- cells and 1 in 56,614 forPage 11 of 15
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populations enriched (basal) or depleted (luminal) for stem cell
activity, are fully consistent with the current estimate of 1 in
20,636 cells from the total virgin epithelium and suggest that
cell purification lowers the ability of transplanted cell isolates
to generate outgrowths. It may be that transplanting of total
mixed mammary cells enhances the rate of successful trans-
plants because of co-transplant of nonepithelial cells that act
to stimulate the outgrowth of the stem cells. Alternatively, it
may be that the sorting procedure itself is deleterious. Poten-
tially, both factors may be relevant. Importantly, however, this
does not mean that the differences between outgrowth poten-
tial are due to differential viability between the cells [11].
It should also be noted that transplantation at limiting dilution
into cleared fat pads is forcing stem/progenitor cells into a
behaviour they would not normally perform physiologically dur-
ing routine tissue turnover or pregnancy-dependent epithelial
expansion. This may result in failure of some genuine stem
cells to form outgrowths or may allow more differentiated pro-
genitors to reacquire primitive stem cell-like features and gen-
erate outgrowths, as has been recently reported for
differentiating spermatogonial progenitors [43]. Nevertheless,
it is still the case that the relative cleared fat pad transplant
potential of the different mammary epithelial populations
reflects the relative enrichment or depletion of stem cells.
Transplantation experiments first suggested that mammary
epithelial stem cells were most strongly enriched in the basal
cell layer [11,24,26,27], and this was confirmed by the recent
report from Taddei and colleagues, who knocked out the stem
cell marker β1-integrin in the basal cell layer of the mammary
epithelium in mice [28]. This blocked mammary stem cell func-
tion and gave a phenotype that included ductal outgrowth
defects in the virgin mice. Knockout of β1-integrin in alveolar
progenitors [32] did not affect the virgin tissue but did affect
pregnancy-dependent development [32,44]. Therefore,
although cell separation and transplantation experiments do
have potential limits, the results from them are supported by
data from the intact animal.
Siwko and colleagues have recently demonstrated that preg-
nancy results in a twofold reduction in stem cell numbers, a
conclusion apparently at odds with the findings we present
here. There are, however, three main differences between the
studies. First, Siwko and colleagues used fewer animals as
donors and did not keep them at a consistent age when tissue
was harvested. We used larger pools of animals for each har-
vest (at least 10 mice for each experiment) and all were at the
same timepoint, as illustrated in Figure 1a. Second, the trans-
plants of Siwko and colleagues were carried out with unsorted
total mammary cells. This probably explains the overall differ-
ence in take rate (1 in 2,608 for virgin cells from Siwko and col-
leagues, and 1 in 20,636 for virgin cells from our data; see
discussion above). Third, and most important, Siwko and col-
leagues mated their mice at 5 weeks of age, early in puberty,
whereas we mated our mice at 9 weeks of age when the mam-
mary epithelium is essentially fully matured.
Although these results will need to be confirmed by a future
analysis in parallel, they suggest that pregnancy during
puberty reduces stem/progenitor cell numbers, but a preg-
nancy occurring once the gland is fully developed does not.
Considering the clear epidemiological data that an early preg-
nancy is protective against breast cancer, but the protective
effect is gradually lost with increasing age prior to first full-term
pregnancy [2], this suggests a relationship between changes
in stem cell numbers and alterations in breast cancer risk.
However, a direct functional link remains to be proven. If there
is such a link, it is unlikely to be straightforward as mammary
stem cells are ER- [10,11] but pregnancy specifically protects
against ER+PR+ breast cancer. It is thought that normal tissue
stem cells are important targets for tumourigenic change
because of their long in vivo lifespan, and it has been sug-
gested that different breast cancer subtypes have their origin
in different stem/progenitor cell types [45-47]. It is possible
that if the target for generation of ER+PR+ tumours is an ER+
progenitor, then a reduction in ER- stem cell numbers may
reduce the rate at which ER+ progenitors are formed, reducing
the size of the target population for transformation. Alterna-
tively, as discussed above, oestrogen may have ER-independ-
ent effects on stem cells or the effects may be mediated
through paracrine interactions with ER+ differentiated cells.
In any case, it is highly likely that the alterations in the breast
cancer risk profile caused by pregnancy are multifactorial in
origin and include other mechanisms besides the potential for
alteration to stem/progenitor cell populations [2]. Such mech-
anisms may include changes in oestrogen responsiveness
[48-50] or gene expression [51-53] of cells, or cell subsets,
within the mammary gland. Changes in the hormonal milieu of
the body [48,54,55] have also been proposed to mediate the
protective effects of parity, possibly through alterations in the
stem cell niche [56]. Manipulation of hormone levels can mimic
the protective effects of pregnancy [54,55], and administra-
tion of insulin-like growth factor 1 can re-establish the sensitiv-
ity of the parous mammary gland to carcinogenesis [57].
Future studies comparing changes in stem cell numbers in ani-
mals mated during puberty or at maturity should therefore
include hormonal manipulations followed by treatment with
carcinogens. This will enable assessment of whether changes
in stem cell numbers in early versus late pregnancy do indeed
correlate with parity-dependent resistance to carcinogenesis
and, if they do, whether insulin-like growth factor 1 treatment
not only removes the resistance but simultaneously increases
stem cell numbers. Such data would strongly support a mech-
anistic connection between parity-mediated protection from
ER+PR+ breast cancer and changes in stem cell numbers as a
result of early, but not late, pregnancy.Page 12 of 15
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There are no significant differences in stem/progenitor cell
numbers between the mammary epithelium derived from
mature adult mice (9 weeks old) that have been through a full-
term pregnancy and lactation, followed by 7 weeks of involu-
tion and remodelling, compared with the mammary epithelium
derived from AMV mice. In contrast, recent data have shown
that animals mated at 5 weeks of age have a twofold reduction
in stem/progenitor cell numbers [23]. Given the association
between early, but not late, pregnancy and breast cancer risk
reduction in humans, this finding is striking and suggestive –
although a mechanistic connection between stem cell num-
bers and breast cancer risk remains to be established.
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